Telangana Hyderabad - Bharat Biotech begins clinical trials of TB vaccine on adults
On Sunday, Bharat Biotech international Ltd announced that adult clinical trials for the Mtbvac tuberculosis vaccine had begun in India. According to a press statement from Bharat Biotech, this is the first vaccination against tuberculosis produced from a human source by the Spanish biopharmaceutical company, Biofabri.
According to the press release, Mtbvac is being developed for two purposes: first, to prevent tuberculosis in adults and adolescents, for whom there is presently no effective vaccine, and second, to serve as a more potent and possibly longer-lasting vaccination than BCG (bacillus Calmette Guerin) for babies.
Bharat Biotech and Biofabri work closely together to conduct the studies.
According to the press release, Mtbvac is being developed for two purposes: first, to prevent tuberculosis in adults and adolescents, for whom there is presently no effective vaccine, and second, to serve as a more potent and possibly longer-lasting vaccination than BCG (bacillus Calmette Guerin) for babies.
Bharat Biotech and Biofabri work closely together to conduct the studies.
A pivotal safety, immunogenicity, and effectiveness study has been scheduled to begin in 2025 as part of the ongoing trials to assess the safety and immunogenicity of Mtbvac, according to the announcement.
Testing adults and teenagers in the nation where 28% of all tb infections worldwide are concentrated is a huge step. tb is still one of the most common infectious causes of mortality worldwide, particularly in India, according to Esteban Rodriguez, CEO of Biofabri.
Testing adults and teenagers in the nation where 28% of all tb infections worldwide are concentrated is a huge step. tb is still one of the most common infectious causes of mortality worldwide, particularly in India, according to Esteban Rodriguez, CEO of Biofabri.
"With clinical trials in India, our quest for a more effective vaccine against tuberculosis received a big boost today," stated krishna Ella, Executive Chairman of Bharat Biotech. Today marks a significant advancement toward our objective of creating tb vaccinations to prevent illness in adults and adolescents.
The Mtbvac vaccine cleared many checks and balances before going into clinical testing in India. A double-blind controlled Phase-3 clinical study in neonates has been initiated in 2023 to compare the vaccine with the existing BCG vaccination, after the recent conclusion of a Phase-2 dosage finding trial.
Up to 7,000 babies from Senegal, 60 from Madagascar, and 7,000 from south africa will receive vaccinations. According to the announcement, almost 1,900 newborns have received vaccinations thus far.
The Mtbvac vaccine cleared many checks and balances before going into clinical testing in India. A double-blind controlled Phase-3 clinical study in neonates has been initiated in 2023 to compare the vaccine with the existing BCG vaccination, after the recent conclusion of a Phase-2 dosage finding trial.
Up to 7,000 babies from Senegal, 60 from Madagascar, and 7,000 from south africa will receive vaccinations. According to the announcement, almost 1,900 newborns have received vaccinations thus far.